Watch the recorded webcast from Egetis’ Capital Markets Day

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatment of serious diseases with significant unmet medical needs in the orphan drug segment

Emcitate®

Our lead product candidate

Pipeline

General Corporate presentation

Press Releases

November 21, 2022

Egetis to participate at upcoming investor conferences

Read more

November 18, 2022

Egetis continues to strengthen the commercial and medical affairs organizations for the expected launch of Emcitate® in 2024

Read more

Regulatory

November 8, 2022

Interim report January-September 2022

Read more

Upcoming event

December 1, 2022

Erik Penser Bank Temadag - Healthcare

Latest presentation

November 24, 2022

Redeye interview with CEO Nicklas Westerholm

Latest Report

November 8, 2022

Q3 Report 2022

Calendar and upcoming reports

December 1, 2022

Erik Penser Bank Temadag - Healthcare

December 15, 2022

DNB Nordic Healthcare Conference

February 22, 2023

Year-end Report Q4 2022

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com

Cookies
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept all”, you consent to the use of ALL the cookies. However, you may visit "Settings" to provide a controlled consent. Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
Save Accept all